• Product search:
About Us Location:Home >> About Us


Company Profile


AbMax Biotechnology Co., Ltd. was established in 2006 and now is a high-tech enterprise and training base for the national life science and technical personnel. AbMax has the world’s most advanced one-stop technology platform for antibodies and kits researching, which has the monoclonal antibody developed in an average of 46 days with a high success rate of 90%. Moreover, AbMax is also the fastest, best and most competitive service provider of antibody developing in China and one of the world’s best service providers of antibody developing.


AbMax, as a member of biomedical field in the capital scientific and technological condition platform, is the training base of BeijingNormalUniversity and also joins the Alliance of Bio-Box Outsourcing, China (ABO). AbMax has 300 square meters of office and 1200 square meters of experimental base, including the cell biology laboratory, the molecular biology laboratory, the biochemistry laboratory, the animal laboratory facilities in line with AAALAC and the GMP workshop of diagnostic reagents.


After passing the ISO9001:2008 Quality Management System Certificate in 2009, AbMax has stepped a higher level in the technical service and the management of production quality and greatly improved its competitiveness.


In the past six years, AbMax provided services for a number of multinational pharmaceutical companies, the domestic and foreign well-known research units and bio-pharmaceutical enterprises and successfully developed thousands of high quality monoclonal antibodies for the antibody drug, protein, peptide, pathogens, small molecules and other antigens and dozens of kits. AbMax also undertook a dozen government major research projects and established the largest pathogen antibody library for emerging/outbreaking infectious diseases in China.


AbMax’s research team, led by Chinese-American scientist and entrepreneur, Dr. Sun Le, all have a bachelor degree or above, including 4 doctors and 8 masters.


Management Team

President & CEO: Dr. Le Sun, World Record Holder of Monoclonal Antibody R&D


Dr. Sun has more than 14 years of biotechnology management experience in the US in business and product development, strategic planning, partnering, and licensing. He founded A&G Pharmaceutical Inc, in 2000. Under his leadership, within 18 months, A&G reached an agreement to co-develop a monoclonal antibody-based drug with MedImmune for treatment of human breast cancer. A&G now has two additional diagnostic kits ready to go into clinic trials. An expert in the development and production of growth factors and antibodies, Dr. Sun has worked with a network of more than 200 preeminent cell biologists in the signal transduction field to commercialize their scientific discoveries. In 1990, he personally launched a monoclonal anti-phosphotyrosine antibody, clone 4G10, which revolutionized signal transduction research. Previously, Dr. Sun was Director of Research and Development at Upstate Biotechnology Inc., a market leader in the biotechnology supplies sector that supplies more than 1,000 research reagents for cancer biology. His team introduced more than 600 new products to the cancer research market, including numerous kinases and phosphatases for high-throughput drug screening and luminex-based immunoassays for diagnostic applications. Prior to that, he served as Director of Production at Upstate Biotechnology. Dr. Sun received MS degrees in chemical engineering from the Chinese Academy of Light Industry and PhD in biochemistry/cell biology from Tsinghua University, Beijing, China. Dr. Sun spent two years as a postdoctoral fellow in Dr. David Barnes’ lab at Oregon State University, where he established primary cultures of zebrafish embryonic stem cells.
Dr. Sun founded Welson Phamaceuticals, Inc and AbMax Biotechnology Co., Ltd after coming back to China in 2004. Dr. Sun is a professor of Beijing Normal University. He has been awarded with Zhongguancun Excellent Talent Returned from Overseas and Talent Returned from Overseas of Zhe Jiang Province.

Vice President of R&D: Dr. Huaming Jin


Dr Jin received Ph.D from University of Wisconsin and worked as a postdoctoral fellow in California Institute of Technology. Dr. Jin is an expert on antibody humanization and large-scale expression.

Vice President of Business Development: Cuijuan Zhang


Ms. Zhang received Msc degree from Shimane University and Bachelors degree from China Agricultural University.